Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesevatinib in pediatric ARPKD
NCT03096080Phase 1Completed
- Sponsor
- Kadmon
- Start
- Aug 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tesevatinib in autosomal recessive polycystic kidney disease (ARPKD) (3 cohorts), sponsored by Kadmon. Primary endpoint: Evaluation of the safety and tolerability of a single dose tesevatinib liquid formulation at 2 weeks. Started Aug 2017; status: completed.
02
Drugs
tesevatinib
03
Conditions
autosomal recessive polycystic kidney disease (ARPKD)
Beyond the preview
Go deeper on NCT03096080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096080.